Continuous intrathecal baclofen infusion for symptomatic generalized dystonia

Neurosurgery

Volumn 38, Issue 5, 1996, Pages 934-939

  Albright, A Leland ^a,b   Barry, Margaret J ^a   Fasick, Pat ^a   Barron, Wendy ^a   Shultz, Barbara ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Baclofen; Cerebral palsy; Dystonia; Hallervorden Spatz; Movement disorders

Indexed keywords

BACLOFEN; CHLORAL HYDRATE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; TRIHEXYPHENIDYL;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL MENINGITIS; CEREBRAL PALSY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; DYSTONIA; FEMALE; HALLERVORDEN SPATZ DISEASE; HUMAN; INFUSION PUMP; INTRATHECAL DRUG ADMINISTRATION; LETHARGY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; THALAMOTOMY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BACLOFEN; CEREBRAL PALSY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; FEMALE; FOLLOW-UP STUDIES; HALLERVORDEN-SPATZ SYNDROME; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MALE; MUSCLE RELAXANTS, CENTRAL; NEUROLOGIC EXAMINATION; TREATMENT OUTCOME;

EID: 0029939071     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199605000-00015     Document Type: Article

References (29)

1. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J: Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270:2475-2477, 1993.
2. Albright AL, Barry MJ, Hoffmann P: Intrathecal L-baclofen in treatment of cerebral spasticity: Case report. Neurology 42:2110-2111, 1995.
3. Albright AL, Cervi A, Singletary J: Intrathecal baclofen for spasticity in cerebral palsy. JAMA 265:1418-1422, 1991.
4. Alexander GE, Crutcher MD: Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 13:266-271, 1990.
5. Birkmayer W, Danielcsyk W, Weiler G: Zur objektivierbarkeit des motonolytischen effecktes eines aminobuttersaurederivates (Ciba 34 647-Ba). Wein Med Wochenschr 117:7-9, 1967.
6. Brandt NJ, Gregersen N, Christensen E, Gron IH, Rasmussen K: Treatment of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria): Experience with diet, riboflavin, and GABA analogue. J Pediatr 94:669-673, 1979.
7. Chevalier G, Deniau JM: Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 13:277-280, 1990.
8. Coffey RJ, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, Herman R, Shetter AG, Levy R, Gill B, Smith R, Wilberger J, Loeser JD, Chabal C, Feler C, Robertson JT, Penn RD, Clarke A, Burchiel KJ, Leibrock LG: Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J Neurosurg 78:226-232, 1993.
9. Davidoff RA: Antispasticity drugs: Mechanisms of action. Ann Neurol 17:107-116, 1985.
10. Davidoff RA, Sears ES: The effects of Lioresal on synaptic activity in the isolated spinal cord. Neurology 24:957-963, 1974.
11. DeLong MR, Crutcher MD, Georgopoulos AP: Primate globus pallidus and subthalamic nucleus: Functional organization. J Neurophysiol 53:530-543, 1985.
12. Fahn S: Systemic therapy of dystonia. Can J Neurol Sci 14:528-532, 1987.
13. Fahn S, Marsden CD, Calne DB: Classification and investigation of dystonia, in Marsden CD, Fahn S (eds): Movement Disorders 2. London, Butterworth, 1987, pp 332-358.
14. Gerlach J, Rye T, Kristjansen P: Effect of baclofen on tardive dyskinesia. Psychopharmacol Bull 56:145-151, 1978.
15. Glazer WM, Moore DC, Bowers, Bunney BS, Roffman M: The treatment of tardive dyskinesia with baclofen. Psychopharmacol Bull 87:480-483, 1985.
16. Greene P: Baclofen in the treatment of dystonia. Clin Neuropharmacol 4:276-288, 1992.
17. Greene P, Shale H, Fahn S: Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3:46-60, 1988.
18. Gutenet PG, Aghajanian GK: ACh, substance P and met enkephalin in the locus coeruleus: Pharmacological evidence for independent sites of action. Eur J Pharmacol 53:319-328, 1979.
19. Hornykiewicz O, Kish SF, Becker LE, Farley I, Shannak K: Brain neurotransmitters in dystonia musculorum deformans. N Engl J Med 315:347-353, 1988.
20. Lees AJ, Shaw KM, Stern GM: Baclofen in Parkinson's disease. J Neurol Neurosurg Psychiatry 41:707-708, 1978.
21. Manyam BV, Ferraro TN, Hare TA: Evaluation of amino acid neurotransmitters, related compounds and precursors in dystonia. Adv Neurol 50:203-209, 1988.
22. Marsden CD: The focal dystonias. Semin Neurol 2:324-333, 1982.
23. Marsden CD, Obeso JA, Zarranz JJ, Lang AE: The anatomical basis of symptomatic hemidystonia. Brain 108:463-483, 1985.
24. Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF: Intrathecal baclofen for intractable axial dystonia. Neurology 41: 1141-1142, 1991.
25. B receptor agonist. Tokai J Exp Clin Med 14:375-380, 1989.
26. Penn RD: Intrathecal baclofen for spasticity of spinal origin: Seven years of experience. J Neurosurg 77:236-240, 1992.
27. Saint Hilaire MH, Burke RE, Bressman SB, Brin MF, Fahn S: Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology 41:216-222, 1991.
28. B receptors on neurones in rat brain slices. Br J Pharmacol 101:949-957, 1990.
29. Silbert PL, Stewart-Wynne EG: Increased dystonia after intrathecal baclofen. Neurology 42:1639-1640, 1992 (letter).